Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
102.34
+0.04 (0.04%)
At close: Jan 30, 2026, 4:00 PM EST
102.21
-0.13 (-0.13%)
After-hours: Jan 30, 2026, 7:55 PM EST
Exact Sciences Revenue
Exact Sciences had revenue of $850.74M in the quarter ending September 30, 2025, with 20.05% growth. This brings the company's revenue in the last twelve months to $3.08B, up 14.47% year-over-year. In the year 2024, Exact Sciences had annual revenue of $2.76B with 10.37% growth.
Revenue (ttm)
$3.08B
Revenue Growth
+14.47%
P/S Ratio
6.23
Revenue / Employee
$440,290
Employees
7,000
Market Cap
19.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.76B | 259.10M | 10.37% |
| Dec 31, 2023 | 2.50B | 415.49M | 19.93% |
| Dec 31, 2022 | 2.08B | 317.19M | 17.95% |
| Dec 31, 2021 | 1.77B | 275.70M | 18.49% |
| Dec 31, 2020 | 1.49B | 615.10M | 70.19% |
| Dec 31, 2019 | 876.29M | 421.83M | 92.82% |
| Dec 31, 2018 | 454.46M | 188.47M | 70.86% |
| Dec 31, 2017 | 265.99M | 166.61M | 167.66% |
| Dec 31, 2016 | 99.38M | 59.94M | 151.99% |
| Dec 31, 2015 | 39.44M | 37.64M | 2,093.38% |
| Dec 31, 2014 | 1.80M | -2.35M | -56.61% |
| Dec 31, 2013 | 4.14M | - | - |
| Dec 31, 2012 | 4.14M | -19.00K | -0.46% |
| Dec 31, 2011 | 4.16M | -1.18M | -22.10% |
| Dec 31, 2010 | 5.34M | 586.00K | 12.32% |
| Dec 31, 2009 | 4.76M | 5.63M | - |
| Dec 31, 2008 | -867.00K | -2.67M | - |
| Dec 31, 2007 | 1.80M | -2.95M | -62.15% |
| Dec 31, 2006 | 4.75M | 500.00K | 11.76% |
| Dec 31, 2005 | 4.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Labcorp Holdings | 13.77B |
| Quest Diagnostics | 10.85B |
| ICON Public Limited Company | 8.10B |
| Illumina | 4.29B |
| Mettler-Toledo International | 3.94B |
| Waters | 3.11B |
| Revvity | 2.81B |
| Medpace Holdings | 2.36B |
EXAS News
- 3 days ago - Alger Small Cap Focus Fund Q4 2025 Portfolio Update - Seeking Alpha
- 6 days ago - Alger Small Cap Growth Fund Q4 2025 Portfolio Update - Seeking Alpha
- 10 days ago - Alger Mid Cap Focus Fund Q4 2025 Portfolio Update - Seeking Alpha
- 4 weeks ago - Top 2 Health Care Stocks That May Crash In Q1 - Benzinga
- 4 weeks ago - Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims - GlobeNewsWire
- 7 weeks ago - Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS - Business Wire
- 2 months ago - Top 2 Health Care Stocks You May Want To Dump This Month - Benzinga
- 2 months ago - Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium - Business Wire